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Abstract
Early acquisition of Pseudomonas aeruginosa is associated with a poorer prognosis in patients with
cystic fibrosis. We investigated whether polymorphisms in CD14, the lipopolysaccharide receptor,
increase the risk of early infection. Forty-five children with cystic fibrosis were investigated with
annual bronchoalveolar lavage (BAL) and plasma sCD14 levels. Plasma sCD14 levels were
significantly lower in children from whom P.aeruginosa was subsequently isolated (492.75 µg/ml vs.
1339.43 µg/ml, p = 0.018). Those with the CD14 -159CC genotype had a significantly increased
risk of early infection with P.aeruginosa suggesting that CD14 C-159T plays a role in determining
the risk of early infection with P.aeruginosa.
Introduction
Cystic fibrosis (CF) is the most common serious, mono-
genic, autosomal recessive disease in Caucasians and
results from mutations in the gene encoding the cystic
fibrosis transmembrane conductance regulator (CFTR).
CF is characterised by variable phenotypic expression,
which is not entirely explained by the allelic heterogeneity
of the pathogenic CFTR mutations, and there is accumu-
lating evidence that much of this phenotypic diversity is
due to the effect of modifier genes [1]. Pseudomonas aeru-
ginosa, an environmental organism, is the most important
pathogen in patients with CF as chronic infection results
in a more rapid decline in lung function and reduced sur-
vival [2].
CD14, a key gene of the innate immune system, functions
as a receptor for lipopolysaccharide (LPS), a constitutive
element of the P.aeruginosa cell wall, and is a potential
modifier of severity in patients with CF. CD14 is expressed
in both a membrane-bound form on macrophages,
monocytes and neutrophils (mCD14) and soluble form
in serum (sCD14). A polymorphism in the CD14 gene
promoter (C-159T) has an allele frequency of approxi-
mately 50% in Europeans [3]. The -159C allele is associ-
ated with lower circulating levels of sCD14 in healthy
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have been shown to increase the magnitude of airway
neutrophil response to LPS [4], whereas CD14 receptor
blockade results in a reduction in the deleterious systemic
responses that occur in sepsis, due to a reduction in pro-
inflammatory cytokines but at the expense of an increased
bacterial load [5]. Hence, CD14 may play a pivotal role in
determining the balance of infection and inflammation in
CF. Increased expression of CD14 may be associated with
more inflammation but a reduced bacterial load, whereas
reduced expression may result in less inflammation but a
greater bacterial load.
We hypothesised that P.aeruginosa infection would be
acquired earlier in children with the -159CC genotype.
Methods
A prospective, population-based, cohort of children with
CF was recruited from the only tertiary paediatric hospital
in Western Australia, which cares for all children with CF
in the state. Annual bronchoscopy, performed through a
laryngeal mask to minimise the risk of upper airway con-
tamination, was done routinely from diagnosis until 7
years of age in all children with CF. Children diagnosed
after the neonatal period, whose first BAL was positive for
P.aeruginosa were excluded from this analysis, as in this
situation it could not be determined when they had ini-
tially acquired this pathogen.
All children with a positive BAL culture for P.aeruginosa,
which was defined as >10,000 CFU/ml, were admitted to
hospital for further treatment. Blood was collected for
genetic studies and subjects were genotyped for the CD14
promoter polymorphism as previously described [3].
Plasma samples taken at the time of the earliest BAL, when
the children were not infected with P.aeruginosa, was avail-
able for measurement of sCD14 levels in 31 children.
Plasma sCD14 levels were determined using a commer-
cially available enzyme-linked immunosorbent assay
(ELISA) kit (R&D Systems, Minneapolis, USA).
The Kaplan-Meier survival method was used to explore
the difference in the P.aeruginosa free survival rates
between CD14 genotype groups. As children in the study
were not the same age, data was censored for individual
children who were known to have not isolated P.aerugi-
nosa at the time of their last BAL and this information was
incorporated into the analysis. Breslow test (Breslow Gen-
eralized Wilcoxon Test) was employed to compare the dif-
ference in the survival curves of acquisition of P.
aeruginosa in the three CD14 genotype groups. Multivari-
ate Cox regression was used to estimate the relative risks
after adjustment for potential confounding factors includ-
ing age, sex, CFTR mutation and nutritional status. Plasma
sCD14 levels were analysed by ANOVA and all the statis-
tical analyses were performed using SPSS for Windows
(Version 11).
Parents of all participants gave informed consent and the
Ethics Committee of King Edward Memorial and Princess
Margaret Hospitals, Western Australia, approved the
study.
Results
Forty-five children (22 male), aged 0.6–6.6 years (mean
3.25 years) were studied, of whom 25/45 (55%) were
DF508 homozygous and 20/45 DF508 heterozygous. CF
was diagnosed at a mean age of 0.23 yrs (95%CI 0.06–0.4
yrs), with 73% diagnosed in the newborn period. There
was no significant difference between CFTR mutation (p =
0.74), gender (p = 0.38), nutritional status (weight for
height z scores) (p = 0.39) or socio-economic status (p =
0.29) in those who did and did not isolate P.aeruginosa.
CD14 genotype frequencies at position -159 were: CC 12/
45 (27%), CT 20/45 (44%), TT 13/45 (29%). P.aeruginosa
was isolated from thirteen children (29%) and the mean
age of acquisition was 2.26 years (95% CI 1.29–3.25).
Subjects with CD14 -159CC appeared to isolate P.aerugi-
nosa at a younger age (mean = 1.1 years, 95%CI = 0.2–1.9
years) than -159CT (mean = 2.8 years, 95%CI = 1.3–4.2
years) and TT subjects (mean = 3.3 years), although this
difference was not statistically significant (p = 0.19).
Figure 1 shows the P.aeruginosa free survival curves of the
three CD14 genotype groups. The probability of children
remaining free of P.aeruginosa with -159CC is consistently
below that of children who are CT or TT and the curve for
children with CT is below that of children with TT. For
example, at 2 years of age, the % children remaining unin-
fected with P.aeruginosa is 55% vs. 82% vs. 100% for CC,
CT and TT respectively.
Compared with -159TT, children with the CC genotype
had a 10-fold (95%CI = 1.09–92.30, p = 0.042) higher rel-
ative risk and children with the CT genotype had an inter-
mediate 5.5 fold (95%CI = 0.69–44.63, p = 0.108) higher
relative risk of being infected with P.aeruginosa. After
adjustment for CFTR mutation and nutritional status, the
estimated relative risk in children with CC or CT increased
further (RR = 13.32, 95%CI = 1.37–129.13, p = 0.025 and
RR = 6.0, 95%CI = 0.71–51.03, p = 0.101 respectively).
This suggested that independent of CFTR mutation and
nutritional status, those with the C allele had a signifi-
cantly increased risk of being infected with P.aeruginosa. In
addition, there was a significant linear trend across the
three genotype groups, between increasing numbers of C
alleles and increasing likelihood of being infected with
P.aeruginosa (p = 0.015).Page 2 of 4
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ginosa, those who remained free of P.aeruginosa had signif-
icantly higher plasma sCD14 levels: 1339.43 µg/ml
(95%CI 1096.63–1635.98 µg/ml) vs. 492.75 µg/ml
(95%CI 55.7–4359.01 µg/ml), p = 0.018. We found no
significant association between plasma sCD14 levels and
CD14 C-159T (p = 0.38).
Discussion
This study showed an association between CD14 -159CC
and early acquisition of P. aeruginosa in children with CF.
Many CF centres promote aggressive treatment regimes to
eradicate first isolates of P.aeruginosa, and, thus, prospec-
tively identifying a "high risk" group of infants with CF
could have substantial clinical benefit.
CD14 receptor activation results in a strong Th1 cytokine
response, directed through IL-12, in an attempt to eradi-
cate pathogens. The finding of lower plasma sCD14 levels
in children who subsequently isolate P.aeruginosa suggests
that an inadequate pro-inflammatory response to LPS
may place these individuals with CF at greater risk of early
P.aeruginosa acquisition. The lack of association between
CD14 C-159T and plasma sCD14 levels may merely
Kaplan-Meier estimates of proportion of children free from P.aeruginosa by CD14 C-159TFigure 1
Kaplan-Meier estimates of proportion of children free from P.aeruginosa by CD14 C-159T. 1Breslow Test (Breslow General-
ized Wilcoxon Test) 2"Censored" represents the censored observations that arise when the duration of a study is limited.Page 3 of 4
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reflect the small number of subjects in this population,
but may also indicate that in CF there are factors more
critical than CD14 C-159T genotype that determine
plasma sCD14 levels.
Although children with higher sCD14 levels may be rela-
tively protected from earlier acquisition of P.aeruginosa,
when they become colonised they may paradoxically have
a worse outcome, as a result of an over-aggressive and
ineffectual inflammatory response. These latter patients
might potentially benefit from aggressive anti-inflamma-
tory treatment. Thus, the timing of anti-inflammatory
therapy would need to be carefully considered, as inflam-
mation might be beneficial in early life by delaying colo-
nisation with P.aeruginosa, but harmful once infection is
established, due to the over-exuberant inflammatory
response. Therapy that modulates the inflammatory
response might promote the acquisition of pathogens
such as P. aeruginosa in young children with different
genetic susceptibilities.
The results of this study are based on a limited number of
subjects due to the stringent inclusion criteria and the pro-
spective longitudinal design. In addition, the potential
role of other single nucleotide polymorphisms in genes
involved in innate immunity such as Toll-like receptor 4
Asp299Gly [6], Toll-like receptor 2 Arg753Gln [6] and
mannose binding lectin [7], may influence the acquisition
of P.aeruginosa in children with CF and more detailed
investigation of these pathways in CF is indicated. This
study identified the potential association between a com-
mon genetic variant and the early isolation of P.aerugi-
nosa. The CD14 promoter polymorphism may have a
central function in determining the age of first isolation of
P.aeruginosa, with the CC genotype conferring a higher
risk of early isolation and the TT genotype being relatively
protective, emphasising the importance of understanding
the delicate balance between inflammation and infection
that exists in CF.
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